These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 29189002

  • 1. Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.
    Zhang Y, Chen Y, Zhang D, Wang L, Lu T, Jiao Y.
    J Med Chem; 2018 Jan 11; 61(1):140-157. PubMed ID: 29189002
    [Abstract] [Full Text] [Related]

  • 2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA, Sakr H, Ayyad RRA, El-Adl K, Ali MM, Khedr F.
    Anticancer Agents Med Chem; 2018 Jan 11; 18(8):1184-1196. PubMed ID: 29651967
    [Abstract] [Full Text] [Related]

  • 3. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
    Marzouk AA, Abdel-Aziz SA, Abdelrahman KS, Wanas AS, Gouda AM, Youssif BGM, Abdel-Aziz M.
    Bioorg Chem; 2020 Sep 11; 102():104090. PubMed ID: 32683176
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA, Abdel-Mohsen HT, El Kerdawy AM, Ragab FAF, Ali MM, Abu-Bakr SM, Girgis AS, El Diwani HI.
    Eur J Med Chem; 2017 Aug 18; 136():315-329. PubMed ID: 28505536
    [Abstract] [Full Text] [Related]

  • 5. Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity.
    Mahmoud HK, Farghaly TA, Abdulwahab HG, Al-Qurashi NT, Shaaban MR.
    Eur J Med Chem; 2020 Dec 15; 208():112752. PubMed ID: 32947227
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM, El-Gaby MSA, El-Adl K, Abd El-Sattar NEA.
    Bioorg Chem; 2020 Nov 15; 104():104350. PubMed ID: 33142416
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.
    Elsayed NMY, Serya RAT, Tolba MF, Ahmed M, Barakat K, Abou El Ella DA, Abouzid KAM.
    Bioorg Chem; 2019 Feb 15; 82():340-359. PubMed ID: 30428414
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
    Roaiah HM, Ghannam IAY, Ali IH, El Kerdawy AM, Ali MM, Abbas SE, El-Nakkady SS.
    Arch Pharm (Weinheim); 2018 Feb 15; 351(2):. PubMed ID: 29323750
    [Abstract] [Full Text] [Related]

  • 12. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
    Al-Hussain SA, Farghaly TA, Zaki MEA, Abdulwahab HG, Al-Qurashi NT, Muhammad ZA.
    Bioorg Chem; 2020 Dec 15; 105():104330. PubMed ID: 33038552
    [Abstract] [Full Text] [Related]

  • 13. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
    Parmar DR, Soni JY, Guduru R, Rayani RH, Kusurkar RV, Vala AG, Talukdar SN, Eissa IH, Metwaly AM, Khalil A, Zunjar V, Battula S.
    Bioorg Chem; 2021 Oct 15; 115():105206. PubMed ID: 34339975
    [Abstract] [Full Text] [Related]

  • 14. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
    El-Adl K, Sakr HM, Yousef RG, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, Abulkhair HS, Eissa IH.
    Bioorg Chem; 2021 Sep 15; 114():105105. PubMed ID: 34175720
    [Abstract] [Full Text] [Related]

  • 15. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
    Mohamed TK, Batran RZ, Elseginy SA, Ali MM, Mahmoud AE.
    Bioorg Chem; 2019 Apr 15; 85():253-273. PubMed ID: 30641320
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments.
    Wang R, Liu H, You YY, Wang XY, Lv BB, Cao LQ, Xue JY, Xu YG, Shi L.
    Bioorg Med Chem Lett; 2021 Mar 15; 36():127788. PubMed ID: 33460739
    [Abstract] [Full Text] [Related]

  • 19. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.
    Abou-Seri SM, Eldehna WM, Ali MM, Abou El Ella DA.
    Eur J Med Chem; 2016 Jan 01; 107():165-79. PubMed ID: 26590508
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.
    Zeidan MA, Mostafa AS, Gomaa RM, Abou-Zeid LA, El-Mesery M, El-Sayed MA, Selim KB.
    Eur J Med Chem; 2019 Apr 15; 168():315-329. PubMed ID: 30826508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.